FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma By Ogkologos - August 22, 2025 740 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Polatuzumab Vedotin April 14, 2022 Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in... June 30, 2026 After Losing His Mom To Breast Cancer, Man Founds ‘Not Just... September 5, 2019 Many Men with Metastatic Prostate Cancer Are Not Getting the Recommended... February 18, 2025 Load more HOT NEWS What’s Your Mantra? What Survivors Should Know When Transitioning From Cancer Care to Primary... How and When to Wash Your Reusable Cloth Mask and When... Programme Highlights of the ESMO Virtual Congress 2020 [ESMO Media Alert]
